+59.7%
GDXJ vs MRNA
+511.3%
-451.6%
-41.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.5% | -2.2% | -0.3% | -2.3% |
| 7D | +0.2% | +5.5% | -5.3% | -0.3% |
| 30D | +17.9% | +158.7% | -140.9% | 0.0% |
| 3M | +15.3% | +182.1% | -166.8% | -5.3% |
| 6M | -9.4% | +151.8% | -161.3% | -24.2% |
| YTD | +13.4% | +393.6% | -380.2% | -17.6% |
| 1Y | +59.7% | +499.5% | -439.8% | +11.8% |
| All | +59.7% | +511.3% | -451.6% | +11.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling